Insider Trading March 13, 2026

IonQ Director Disposes $93K in Shares as Company Advances Research and Secondary-Share Filings

Director and special advisor Raymond John W sold 2,800 IonQ shares on March 12, 2026; firm continues partnerships and secondary-share registrations amid mixed valuation signals

By Nina Shah IONQ
IonQ Director Disposes $93K in Shares as Company Advances Research and Secondary-Share Filings
IONQ

Raymond John W, a director and special advisor at IonQ Inc (NYSE: IONQ), executed a sale of 2,800 common shares on March 12, 2026, for $33.34 each, yielding $93,352, according to a Form 4 filed with the SEC. After the sale he holds 83,963 shares. The quantum computing company has seen shares trade near $32.98 while delivering a 32% return over the last year, and has announced several strategic partnerships and prospectus supplements for share resales.

Key Points

  • Raymond John W sold 2,800 IonQ shares on March 12, 2026 at $33.34 each, totaling $93,352; he now directly holds 83,963 shares.
  • IonQ shares traded at $32.98, down 7.7% over the past week but up about 32% over the last year; 52-week high is $84.64.
  • Company activity includes prospectus supplements for resale of 5.1 million shares and 2.56 million shares tied to the University of Cambridge, partnerships with Cambridge and the Applied Research Laboratory for Intelligence and Security, and a Benchmark price-target reduction to $65 while retaining a Buy rating.

According to a Form 4 filed with the Securities and Exchange Commission, Raymond John W, who serves as both a director and special advisor to IonQ Inc (NYSE: IONQ), sold 2,800 shares of the company’s common stock on March 12, 2026. The shares were disposed of at $33.34 apiece, producing a total transaction value of $93,352. Following that transaction, Raymond John W is recorded as directly owning 83,963 shares of IonQ common stock.

At the time of reporting, IonQ shares were trading at $32.98, a level that reflects a 7.7% decline over the previous week. Over a 12-month horizon, the stock has returned roughly 32%, though it remains substantially below its 52-week peak of $84.64. Independent analysis cited by market services indicates the stock appears fairly valued at present levels, using Fair Value estimates and additional analytical guidance.

Beyond the insider sale, IonQ has been active on several corporate and strategic fronts:

  • Regulatory filings include a prospectus supplement for the resale of 5.1 million shares by certain stockholders. This follows an earlier filing related to the resale of 2.56 million shares held by the University of Cambridge. Both filings are framed as part of the contractual arrangements detailed in the respective prospectus supplements.
  • The company confirmed a partnership with the University of Cambridge to create the IonQ Quantum Innovation Centre, an initiative described as focused on multiple areas of quantum-computing research.
  • IonQ also announced a collaboration with the Applied Research Laboratory for Intelligence and Security to develop a quantum security framework, an effort sponsored by the Secretary of the Air Force.
  • In the equity research arena, Benchmark lowered its price target on IonQ to $65 from $75 but maintained a Buy rating, noting expectations that the company’s fourth-quarter results and full-year guidance will help address concerns about commercialization of quantum technologies.
  • Company performance disclosures indicate IonQ’s organic core computing business grew more than 80% year-over-year, representing a meaningful portion of the company’s revenue mix.

The Form 4 sale by Raymond John W is a discrete insider transaction and is recorded alongside corporate developments that include secondary-share registrations and multiple research partnerships. The filings related to share resales and institutional holdings signal further liquidity events for existing shareholders, while partnerships underscore continued investment in research and security applications for quantum computing.

Market participants and observers will likely monitor forthcoming quarterly results and guidance for confirmation of commercial traction, as well as any further insider transactions or shareholder resale activity arising from the prospectus supplements.


Note: This article reports the details contained in the SEC filing and subsequent company announcements. Where information is limited in the filings or company releases, this report reflects only what has been disclosed.

Risks

  • Resale filings for large blocks of stock - the prospectus supplements for 5.1 million shares and 2.56 million Cambridge-held shares could increase share supply and affect market liquidity - impacts equities markets and investor sentiment.
  • Short-term share-price volatility - the stock has fallen 7.7% over the past week and remains well below its 52-week high, reflecting market sensitivity around commercialization and valuation - impacts technology and specialty finance sectors.
  • Dependence on commercialization milestones and quarterly guidance - Benchmark cited upcoming fourth-quarter results and full-year guidance as key to easing commercialization concerns, indicating that operational results will materially influence investor perceptions - impacts investors in quantum computing and related research sectors.

More from Insider Trading

Bank of America International President Sells $4.4 Million in Shares Mar 14, 2026 FirstEnergy Director James F. ONeil Disposes of $402k in Shares Amid Strategic Developments Mar 14, 2026 Will W Anthony Sells $10.3 Million of CF Industries Stock in Two-Day Disposal Mar 13, 2026 CoreWeave CEO Sells $6.7 Million in Class A Shares as Company Posts Rapid FY2025 Revenue Growth Mar 13, 2026 CoreWeave CFO Executes $5.03M Sale After Exercising RSUs Mar 13, 2026